{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-107327","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.359088+00:00","generated_at":"2026-05-30T17:25:17.868661+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioXcel CCO Matthew Wiley departs; severance includes 9-mo salary, consulting through 2024","bullets":["Matthew Wiley (SVP, Chief Commercial Officer) separated on Oct 2, 2024; severance agreement signed Oct 3.","Severance: 9 months base salary continuation, prorated 2024 bonus, 9 months COBRA reimbursement.","Consulting agreement with Wiley's LLC at $330/hr, $7,500 retainer, runs through Dec 31, 2024.","Standard release of claims and non-disparagement obligations included in separation agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-107327","json":"https://secwatch.observer/filing/0001104659-24-107327.json","markdown":"https://secwatch.observer/filing/0001104659-24-107327.md","text":"https://secwatch.observer/filing/0001104659-24-107327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/0001104659-24-107327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/tm2425903d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:25:17.868661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee8f6932d6","claim":"Matthew Wiley departed as Senior Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..","evidence_excerpt":"Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “ Company ”), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924107327/0001104659-24-107327-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease employment"},{"label":"Role","value":"Senior Vice President and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}